Literature DB >> 10943632

Allergen immunotherapy: does it work and, if so, how and for how long?

D S Robinson1.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10943632      PMCID： PMC1765945          DOI： 10.1136/thorax.55.suppl_1.s11

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  23 in total

Review 1.  Development of T-cell memory against inhalant allergens: risks for the future.

Authors:  P G Holt
Journal:  Clin Exp Allergy       Date:  1999-06       Impact factor: 5.018

2.  Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy.

Authors:  T Takai; T Yokota; M Yasue; C Nishiyama; T Yuuki; A Mori; H Okudaira; Y Okumura
Journal:  Nat Biotechnol       Date:  1997-08       Impact factor: 54.908

Review 3.  Future directions for allergen immunotherapy.

Authors:  T A Platts-Mills; G A Mueller; L M Wheatley
Journal:  J Allergy Clin Immunol       Date:  1998-09       Impact factor: 10.793

4.  Nasal immunotherapy--not to be sneezed at.

Authors:  B M Haselden; A B Kay
Journal:  Clin Exp Allergy       Date:  1998-04       Impact factor: 5.018

5.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Long-term clinical efficacy of grass-pollen immunotherapy.

Authors:  S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

7.  Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?

Authors:  P White; H Smith; N Baker; W Davis; A Frew
Journal:  Clin Exp Allergy       Date:  1998-03       Impact factor: 5.018

8.  Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis.

Authors:  G Passalacqua; M Albano; L Fregonese; A Riccio; C Pronzato; G S Mela; G W Canonica
Journal:  Lancet       Date:  1998-02-28       Impact factor: 79.321

9.  Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions.

Authors:  B M Haselden; A B Kay; M Larché
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307
View more
  1 in total

1.  Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis.

Authors:  Edmir Américo Lourenço; Eduardo José Caldeira; César Alexandre Fabrega Carvalho; Marcelo Rodriques Cunha; Marcus Vinícius Henriques Carvalho; Saulo Duarte Passos
Journal:  Int Arch Otorhinolaryngol       Date:  2015-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.